Fed. Circ. Says Sumitomo's Expired Drug Patent Moots Appeal
The U.S. Patent and Trademark Office received a win on Friday when the Federal Circuit found that since Sumitomo Pharma's patent on a dosage regimen for a schizophrenia drug expired just...To view the full article, register now.
Already a subscriber? Click here to view full article